Emerging Agents and Combinations to Treat RET Fusion-Positive Lung Cancers

RET Fusion Treatment: Pralsetinib - Targeted Therapies in Lung Cancer 2023Подробнее

2023 Best of Lung: Targeted Therapies in Lung CancerПодробнее

Rare Fusions in NSCLC: RET - Targeted Therapies in Lung Cancer 2023Подробнее

LIBRETTO-001: RET-Fusion Positive Metastatic NSCLCПодробнее

RET Fusion Treatment: Selpercatinib - Targeted Therapies in Lung Cancer 2023Подробнее

New combination and gene therapies for lung cancerПодробнее

RET fusion-positive mNSCLC: selpercatinib and pralsetinibПодробнее

Targeted Therapy for Treatment-Naïve RET Fusion-Positive Lung CancersПодробнее

Treatment of NSCLC With RET FusionsПодробнее

Best New Lung Cancer Treatments for RET MutationПодробнее

The impact of selpercatinib in patients with RET fusion-positive NSCLCПодробнее

Lung Cancer Video Library 2020 - BAUML - Emerging Molecular Targets in NSCLC, RET FusionsПодробнее

Fine-Tuning Biomarker Testing to Identify and Target RET Fusions in NSCLCПодробнее

Selpercatinib Induced Durable Efficacy in RET Fusion-Positive NSCLCПодробнее

[lung] Effect of selpercatinib for RET-positive patientsПодробнее

Improving Clinical Care With Newer Better Therapies for Targeting Actionable gene Fusions in NSCLCПодробнее

ARROW update confirms pralsetinib benefit for RET fusion-positive advanced NSCLC | Stephen LiuПодробнее

GRACEcast - Emerging Molecular Targets in NSCLC- RET Fusions with Dr. Josh BaumlПодробнее

Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid c...Подробнее